Literature DB >> 12065071

Binding properties of the novel, non-peptide CGRP receptor antagonist radioligand, [(3)H]BIBN4096BS.

Marcus Schindler1, Henri N Doods.   

Abstract

BIBN4096BS [[R-(R,(R*,S*)]-N-[2-[[5-amino-1-[[4-(4-pyridinyl)-1-piperazinyl]carbonyl] pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-,1-Piperidinecarboxamide] is a selective calcitonin gene-related peptide (CGRP) receptor antagonist with a picomolar affinity to the CGRP receptor in human neuroblastoma SK-N-MC cells. Here, we describe the characterisation of the binding properties of the tritiated radioanalogue of BIBN4096BS in SK-N-MC cells as well as in marmoset tissue. [(3)H]BIBN4096BS showed reversible and saturable binding to SK-N-MC cells with a K(D) of 0.045 nM. In competition experiments, [3(H)]BIBN4096BS is concentration-dependently displaced from SK-N-MC cell membranes by BIBN4096BS as well as by the endogenous ligand CGRP and its analogues with the rank order of affinity BIBN4096BS>human alpha-CGRP=human beta-CGRP>[Cys(Et)(2,7)]human alpha-CGRP>adrenomedullin (high affinity site)=human alpha-CGRP-(8-37)=human beta-CGRP-(8-37)>calcitonin=amylin. In the marmoset cortex, saturable [(3)H]BIBN4096BS binding was observed with a K(D) of 0.077 nM. CGRP showed biphasic competition of [(3)H]BIBN4096BS binding, whilst BIBN4096BS monophasically displaced its radioanalogue with a K(i) of 0.099 nM. These data, using [(3)H]BIBN4096BS, confirm the high affinity of this novel antagonist for the primate CGRP receptor and demonstrate furthermore that this radioligand is a useful tool to study CGRP receptor pharmacology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065071     DOI: 10.1016/s0014-2999(02)01544-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  G-protein βγ subunits in vasorelaxing and anti-endothelinergic effects of calcitonin gene-related peptide.

Authors:  M J P M T Meens; N J A Mattheij; P B van Loenen; L J A Spijkers; P Lemkens; J Nelissen; M G Compeer; A E Alewijnse; J G R De Mey
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist.

Authors:  Iñaki F Trocóniz; Jan-Markus Wolters; Christiane Tillmann; Hans G Schaefer; Willy Roth
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine.

Authors:  Eric L Moore; Christopher A Salvatore
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat.

Authors:  Kenneth A Petersen; Steffen Birk; Henri Doods; Lars Edvinsson; Jes Olesen
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

5.  Small molecule antagonists of the TGF-beta1/TGF-beta receptor binding interaction.

Authors:  James K Burmester; Sherry A Salzman; Kai Qi Zhang; Richard A Dart
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

6.  CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.

Authors:  D L Hay; S G Howitt; A C Conner; M Schindler; D M Smith; D R Poyner
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

7.  A comparison of the actions of BIBN4096BS and CGRP(8-37) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells.

Authors:  Debbie L Hay; Stephen G Howitt; Alex C Conner; Henri Doods; Marcus Schindler; David R Poyner
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

8.  Identification of specific calcitonin-like receptor residues important for calcitonin gene-related peptide high affinity binding.

Authors:  Sugato Banerjee; Janel Evanson; Erik Harris; Stephen L Lowe; Kathryn A Thomasson; James E Porter
Journal:  BMC Pharmacol       Date:  2006-06-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.